Market analysis report of microsphere preparation in China

Abstract: eight microsphere preparations are on the market in China, with a compound growth rate of 19% in five years (2013-2017) and a sales volume of 4.4 billion yuan in 2017 Compared with the sales volume of 7.49 billion yuan in the Chinese market of all formulations of this product, microsphere formulations account for 58.7% The listing of microspheres in China there are 8 products of microsphere preparation, with a total of 8 manufacturers listed, of which 4 products listed globally are not listed in China, namely: buserelin (listed globally in 1986), naltrexone (listed globally in 2006), paritide (listed globally in 2014) and triamcinolone acetate (listed globally in 2017) Table 1 marketing situation of microspheres / liposomes / long-acting preparations in China data source: marketing situation of pharmaceutical intelligence data microspheres to generic drugs in China a total of 8 microspheres products (5 generic names) are on the market in China Based on the analysis of the sales data of all dosage forms of the products on the market, there were four products with more than 1 billion yuan in 2017, namely octreotide, leuprorelin, risperidone and triptorelin The top three sales volume in 2017 were leuprorelin, octreotide and risperidone, accounting for 37.0%, 23.0% and 18.1% respectively Figure 1 sales trend of microsphere preparations in China market (unit: RMB 100 million) analysis on sales situation of microsphere preparations in China market eight products of microsphere preparations were sold on the market, with sales volume of RMB 3.18 billion in 2017, growing rapidly, with a compound growth rate of 23% in the past five years Figure 2 sales trend of microsphere preparation in China (unit: RMB 100 million) distribution analysis of microsphere preparation brands / manufacturers in China market 8 products (5 common names) in China market have 8 manufacturers listed, analyzed from the following dimensions: (1) product level: the top three sales are leuprorelin, triptorelin and octreotide (2) Enterprise level: at present, there are three enterprises in the production of liangbingruilin, which are Shanghai Lizhu, Beijing Bonte and Japan Takeda The compound growth rate of Shanghai Lizhu and Beijing enbote was over 40% from 13 to 17 years In 2017, the variety of Shanghai Lizhu and Beijing Bonte were all anti Japanese Takeda Triptorelin ranks the second in microsphere preparation products, with two imported enterprises listed in China, namely ferring GmbH company and Ipsen company, both maintaining steady growth, with CAGR (2013-2017) of 25.9% and 8.1% respectively The sales volume of octreotide ranks third, which is the exclusive variety of Novartis, with CAGR (2013-2017) of 34.65%, maintaining a high growth rate Figure 3 proportion of microsphere preparations of enterprises in Chinese market trend analysis of microsphere preparations sales in China there are 8 products on sale, at present, there are three enterprises in production and sales of leuprorelin microsphere preparations, namely, Shanghai Lizhu, Beijing Bonte and Japan Takeda Triptorelin has two manufacturers on sale, Ipsen pharma and ferring GmbH The rest of the products are exclusive Figure 4 proportion of sales of all preparation enterprises of leuprorelin (RMB 100 million) Figure 5 proportion of sales of all preparation enterprises of triptorelin (RMB 100 million) Figure 6 proportion of microsphere preparation in Chinese market trend chart of all dosage forms is not completed to be continued... the content of the article is excerpted from the report catalogue of pharmaceutical intelligence consulting report microsphere liposome Industry Research Report: 1 Overview of microspheres / liposomes 9 Global microspheres / liposomes / other long-acting preparations on the market and market performance 16 China microspheres / liposomes / other long-acting preparations on the market and market performance 43 Analysis of microspheres / liposomes policy 63 5 SWOT analysis of microsphere / liposome preparation........ 71 6 Analysis of competition pattern of domestic microsphere / liposome preparation R & D enterprises......... 73 7 Market prospect analysis of microsphere / liposome preparation........ 80 sprouting This report is excerpted from the microsphere liposome Industry Research Report For the full text of the report, please contact the pharmaceutical intelligence Consultant: Tian Juan 13350326061; Sun Tao 17723945390